Zai Lab(NASDAQ) ZLAB

Zai Lab Limited helps people with serious illnesses by bringing new medicines to market. The company develops treatments for patients in China and the United States. These products focus on medical areas with few existing options.

A Portfolio of Specialized Treatments

• Oncology: Cancer treatments like Zejula for ovarian cancer and Optune, a wearable device that uses electric fields to treat tumors.
• Immunology: Modern therapies such as Vyvgart, which treats adults with generalized myasthenia gravis, a chronic muscle weakness disorder.
• Infectious Diseases: Antibiotics and anti-infectives including Nuzyra for pneumonia and Xacduro for serious hospital-acquired infections.
• Neuroscience: Recently launched KarXT, the first new type of medicine for schizophrenia in adults approved in over 70 years.

Building a Robust Pipeline

• Launched KarXT in mainland China in June 2026 to treat adults with schizophrenia through a new method that targets specific brain receptors.
• Announced a clinical trial collaboration with Amgen in April 2026 to evaluate a lung cancer treatment in combination with other therapies.
• Formed a partnership with Boehringer Ingelheim in April 2026 to study new treatments for neuroendocrine cancers.
• Received Fast Track Designation from the FDA in May 2026 for its drug candidate zoci to treat specific rare tumors.

Bridging Global Science and Local Markets

Zai Lab maintains a dual presence in Greater China and the United States to manage global clinical trials and commercial launches. The company utilizes a licensing model to bring innovative therapies from international partners to patients in the Chinese market.

Key Financial Performance Metrics

• Net product revenue was $105.8 million in the second quarter of 2026, down 3% year over year.
• Research and development expenses reached $61.8 million in the second quarter of 2026, up 22% year over year.
• Net loss was $50.8 million in the three-month period ended June 30, 2026, compared to $40.7 million in the prior year period.
• Cash, cash equivalents, and short-term investments totaled $717.5 million as of June 30, 2026.

Bottom Line

Zai Lab has transitioned from a research-focused firm into a commercial-stage company with eight products launched in China. Its growth depends on expanding its portfolio through both internal discovery and international partnerships.